Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Florian Lordick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8591-9339; OpenAlex author ID A5050136275. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 3, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  3. Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? First author DOI 10.1001/jamaoncol.2021.3603↗
  4. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. Last author DOI 10.1136/esmoopen-2020-000804↗
  5. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  6. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … First author DOI 10.1080/14737140.2017.1369882↗
  7. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pa… Co-author DOI 10.1007/s10637-010-9619-8↗
  8. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. First author DOI 10.1159/000324667↗

Trials 1

  1. Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer Study chair NCT00425841↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorenzo Gervaso · 1 shared paper, 2021 · strength 0.22
  2. Nicola Fazio · 1 shared paper, 2021 · strength 0.22
  3. David Goldstein · 2 shared papers, 2017–2022 · strength 0.19
  4. Timothy Jay Price · 2 shared papers, 2017–2022 · strength 0.19
  5. Eva Segelov · 2 shared papers, 2017–2022 · strength 0.19
  6. Lorraine A. Chantrill · 2 shared papers, 2017–2022 · strength 0.19
  7. Ian Chau · 2 shared papers, 2017–2022 · strength 0.19
  8. Silvia Catanese · 1 shared paper, 2020 · strength 0.16
  9. George E. Pentheroudakis · 1 shared paper, 2020 · strength 0.16
  10. Nick Pavlakis · 1 shared paper, 2022 · strength 0.13
  11. Amitesh Chandra Roy · 1 shared paper, 2022 · strength 0.13
  12. Trevor Leong · 1 shared paper, 2022 · strength 0.13
  13. Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13
  14. Christos Stelios Karapetis · 1 shared paper, 2022 · strength 0.13
  15. Niall Christopher Tebbutt · 1 shared paper, 2022 · strength 0.13
  16. Mike Nguyen · 1 shared paper, 2022 · strength 0.13
  17. Daniel John Renouf · 1 shared paper, 2022 · strength 0.13
  18. Radka Lordick Obermannova · 1 shared paper, 2017 · strength 0.07
  19. Ben J. Lawrence · 1 shared paper, 2017 · strength 0.07
  20. Daniel Gerald Croagh · 1 shared paper, 2017 · strength 0.07
  21. Marc Eric Martignoni · 1 shared paper, 2017 · strength 0.05
  22. Werner Hartwig · 1 shared paper, 2017 · strength 0.05
  23. Florian Otto · 1 shared paper, 2017 · strength 0.05
  24. Pierre Laurent‐Puig · 1 shared paper, 2017 · strength 0.05
  25. Jean‐Robert Delpéro · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.